Skip to main navigation Skip to search Skip to main content

Rethinking clinical trials in the multimorbidity era: the imperative for patient-centered tailored approaches

  • Ana Isabel Gonzalez-Gonzalez*
  • , Elisa Fabbri
  • , Lara Schurmann
  • , Jeanet Blom
  • , Svetlana Puzhko
  • , Amaia Caldero-Larranaga
  • , Nina Grede
  • , Bruce Guthrie
  • , Maria Hanf
  • , Gabriele Meyer
  • , Rafael Perera
  • , Mieke Rijken
  • , Martin Scherer
  • , Susan M. Smith
  • , Michael A. Steinman
  • , Sharon Straus
  • , Jose Maria Valderas
  • , Marjan Van Den Akker
  • , Victor M. Montori
  • , Christiane Muth
  • *Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Background and Objectives: Multimorbidity, the coexistence of two or more chronic conditions, affects about 40% of all adults and over half of adults over 60 years. The complexity of multimorbidity (MM) often renders traditional trial designs inadequate, unable to account for the context of interventions, including the interplay of multiple health conditions in daily life. This gap reduces the generalizability and applicability of their results.Methods: This commentary aims to review the current state of trials targeting or involving patients with MM. Highlighting current limitations and drawing on insights from an international dedicated workshop in Bielefeld, Germany, we identify an ongoing and pressing need for innovative, patient-centered approaches to their design and conduct.Results: We propose a shift toward more holistic and integrative experimental approaches, including developing interventions tailored to the characteristics and needs of patients with MM, establishing relevant outcomes, and enhancing data collection and process evaluation. We specifically advocate for adaptive trial designs, prespecified subgroup analyses, and the incorporation of patient-reported outcomes and experience measures such as burden of care to ensure that research is both comprehensive and reflective of the needs of patients living with MM, their caregivers, and of the clinicians participating in their care. Ethical considerations are discussed in our commentary as well, emphasizing the importance of patient safety, data protection, and informed consent. Finally, we call for the development of specific re-porting guidance, such as a SPIRIT extension tailored to MM trials, to help researchers adapt standard protocols to the complex and het-erogeneous reality of this population.Conclusion: This commentary aims to bridge the gap between research and practice, fostering the development of effective interven-tions that improve patient outcomes and enhance the quality of care for patients living with MM. (c) 2026 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Original languageEnglish
Article number112204
Number of pages8
JournalJournal of Clinical Epidemiology
Volume194
DOIs
Publication statusPublished - 1 Jun 2026

Keywords

  • Multimorbidity
  • Patient-centered trials
  • Adaptative trial design
  • Patient-reported outcomes
  • Real world evidence
  • Complex interventions
  • POPULATION

Fingerprint

Dive into the research topics of 'Rethinking clinical trials in the multimorbidity era: the imperative for patient-centered tailored approaches'. Together they form a unique fingerprint.

Cite this